Wulff, Hansen & Co. Mannkind Corp Transaction History

Wulff, Hansen & Co.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$3.02 - $5.37 $7,550 - $13,425	-2,500 Reduced 15.72%	13,400 $70,000
Q3 2022 Nov 03, 2022	BUY	$2.99 - $4.35 $1,046 - $1,522	350 Added 2.25%	15,900 $49,000
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $62,977 - $83,503	15,550 New	15,550 $68,000

248

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.44B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Wulff, Hansen & Co., based on Form 13F filings with the SEC.

Stay updated on Wulff, Hansen & Co. with notifications on news.